Apr. 6 at 3:19 PM
🚨
$SLS: THE
$1 TRILLION BIDDING WAR BEGINS 💣💰
The AACR data is out and the "Atomic Bomb" (SLS009) just changed the math. While Merck fights to save their
$31B Keytruda throne, Eli Lilly (
$1T Market Cap) and Pfizer are looking for the "Master Switch" to own the future of oncology. 🧬🚀
THE PRICE TARGET REALITY:
🔹
$10B Buyout =
$55/share
🔹
$15B Buyout =
$83/share
🔹
$31B Buyout =
$172/share
WHY THEY PAY:
✅ 2.5x Potency Jump: Shatters cancer with 1/2 the dose.
✅ 6hr Kill Switch: No more waiting days for chemo to work.
✅ 20+ Targets: Not just Ovarian or AML—we’re talking Lung, Colorectal, and Pancreatic.
Merck paid
$6B for single-target plays.
$SLS has the whole arsenal. Whether it's a cash buyout or a stock-swap with Lilly (
$920/share), the floor is set and the data is undeniable. 📈🥊
#SLS #AACR2026
$LLY $PFE $MRK and I didn't even mention the SHORTS yet lol!!!!! We could get
$60+the day of the 80th event or halt --my floor for any talk is
$67